Empasiburbart for MMN: Clinical Update & Biomarker Strategy
Time: 4:30 pm
day: Conference Day One
Details:
- Outlining a comprehensive clinical update on Empasiprubart’s performance in treating MMN, including key efficacy data, patient outcomes, and safety profile from ongoing trials
- Initiating the full complement pathway, generating inflammatory molecules like C3a, C5a, opsonins, and the membrane attack complex
- Highlighting GZMK as a previously unrecognized and important contributor to tissue inflammation across various diseases, suggesting its potential as a novel therapeutic target
